Product information

From Health Canada

New search

The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.

Current status:

Marketed

Current status date:

2017-02-06

Original market date: See footnote 1

2017-02-06

Product name:

HYDROMORPHONE HYDROCHLORIDE INJECTION

Description:

SINGLE USE

Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT) files, can be obtained in the alternate format help section .

DIN:

02460602

Product Monograph/Veterinary Labelling:

Date: 2018-08-28 Product monograph/Veterinary Labelling (PDF version ~ 175K)

Company: 

STERIMAX INC
2770 Portland Drive
Oakville
Ontario
Canada  L6H 6R4

Class: 

Human

Dosage form(s):

Solution

Route(s) of administration:

Intravenous,  Subcutaneous,  Intramuscular

Number of active ingredient(s):

1

Schedule(s):

Narcotic (CDSA I)  

Biosimilar Biologic Drug:

No

American Hospital Formulary Service (AHFS): See footnote 3

28:08.08   OPIATE AGONISTS

Anatomical Therapeutic Chemical (ATC): See footnote 4

N02AA03  HYDROMORPHONE

Active ingredient group (AIG) number:See footnote 5

0108698003

List of active ingredient(s)
Active ingredient(s) Strength
HYDROMORPHONE HYDROCHLORIDE 2 MG / ML

Application information

Related information

Contact us

Version 3.8.0
Date modified: